Industry news

02 May 2016

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2016 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and reported its financial results for the quarter ended March 31, 2016.

Drug development hopefuls 'wish we could turn back time'

Marie Powers / BioWorld

We live in an aging world, according to a U.S. Census Bureau report of the same name issued last month. Based on 2015 data, researchers Wan He and Daniel Goodkind of the Census Bureau and Paul Kowal of the World Health Organization's Study on Global Aging and Adult Health amassed some startling statistics.

Legislative riddles hand courts vital role in shaping biosimilar path

Mari Serebrov / BioWorld

The FDA's slow pace of developing a U.S. biosimilar path that already trails that of other markets has drawn sharp rebukes from Congress and critics, but the regulator isn't the only force shaping the path.

Mobile ad spending up, but pharma's share remains small

Beth Snyder Bulik / FiercePharmaMarketing

Digital ad spending last year was just shy of $60 billion, with pharma accounting for about $3 billion of that, according to the Interactive Advertising Bureau’s annual ad revenue report prepared by PricewaterhouseCoopers. Digital spend grew by 20% year over year overall, with the biggest gains in mobile advertising, which grew 66% to tally $20.7 billion in revenues.

What will next-gen cancer cocktails cost? It's all about value, execs say

Tracy Staton / Fierce Biotech

Immuno-oncology drug developers have heard the debate about drug prices--and not only that. They’re listening. The first two cancer-fighting PD-1 drugs, Merck & Co’s Keytruda and Bristol-Myers Squibb’s Opdivo, both hit the market with six-figure prices. Others are soon to follow, including Roche’s atezolimumab, no doubt bearing similar price tags.

JAMA: Adding 3-D mammography decreases patient recalls, increases cancer detection

Stacy Lawrence / Fierce Medical Devices

Improving the accuracy of breast exams to detect cancer is at the forefront of research agendas since, in recent years, the necessity of routine screening--as well as vigorous surgical and radiation protocols--have been called into question.

Heated iron nanoparticles increase chemo effect

Michael Gibney / FiercePharma

A team of Japanese researchers from several institutions across the country announced they were able to enhance a nanoparticle drug delivery system by applying heat, giving the chemotherapy drug the added benefit of local hyperthermia in head and neck cancers.

Germany’s drug pricing amnesty reset risks pharma backlash

Ben Adams / FiercePharma

Germany’s strict drug pricing controls may be about to get a whole lot harsher as the country’s government is mulling over whether to lift a lucrative pricing amnesty.

Aging R&D: The new, old thing in biotech

John Carroll / FierceBiotech

If you ever wondered what kind of future to expect for R&D on drugs to slow the aging process, pay particularly close attention to this story from The Wall Street Journal. 

Russians move inch closer to solving cardiac arrhythmia problem

Marchmont Innovation News

Russian biologists and physicists have developed technology enabling cardiac cell control with a laser. This is expected to pave the way for creating future solutions that may help rectify cardiac tissue excitability in arrhythmia cases, the Russian news agency RIA Novosti  reported , citing a  project-related article  in PLoS One.